Charts

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m.

Wednesday,HOOKIPA PharmaInc(NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) ...

NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. HOOKIPA’s HB-700 program is designed

NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Compa

Monday,Roche Holdings AG(OTC:RHHBY)announcedtopline data from Phase 3 STARGLO study of Columvi (glofitamab) in ...

HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria, April 10, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA’s Executive Team will host an investor call

Today is shaping up negative for HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shareholders, with the analysts delivering a...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. The post HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

HOOKIPA Pharma (NASDAQ:HOOK) reported its Q4 earnings results on Friday, March 22, 2024 at 07:01 AM. Here's what investors need to know ...

HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with additional patients in Q2 2024; Company will also provide pivotal trial design and development strategy Finalizing Investigational New Drug (IND)-enabling activities for HB-700 for treatment of KRAS mutated cancers IND submission is on track for filing by April 2024, which would trigger a

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s Chief Financial Officer, Reinhard Kandera, will present at the Leerink Partners Global Biopharma Conference on March 13, 2024. Webcast details are available below. Leerink Partners Global Biopharma Conference 2024, Miami, FloridaFireside Chat: Wednesday, M

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Tuesday,Repare Therapeutics Inc(NASDAQ:RPTX) announced to regain global development and commercialization rights to ...

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market ...

HOOKIPA Pharma Inc. (HOOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BK, HCA and HOOK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2023.

HOOKIPA Pharma Inc(NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its ...

Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Gainers OneMedNet (NASDAQ:ONMD) stock rose 172.1% to $1.39 during Monday's pre-market session. The market value of their outstanding ...

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milestone payment associated with submission of Investigational New Drug application HOOKIPA will implement cost saving initiatives, including a reduction of workforce by approximately 30 percent HOOKIPA maintains a

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. (NASDAQ: GILD) is an ...

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024 (‘effective date’). Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe. “

Gainers Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 94.4% to $137.0 during Monday's regular session. The market ...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks ...

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow ...

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly ...

Gainers HOOKIPA Pharma (NASDAQ:HOOK) stock moved upwards by 73.2% to $0.98 during Thursday's regular session. The market value of their ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded ...

Gilead Sciences Inc(NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares ofHOOKIPA Pharma ...

U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Polished.com stock is falling on Thursday as investors in POL react to the company's shares undergoing an extreme rally on Wednesday! The post Why Is Polished.com (POL) Stock Down 38% Today? appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Brenmiller Energy stock is rising on Thursday as investors celebrate shares of BNRG regaining compliance with listing standards. The post Why Is Brenmiller Energy (BNRG) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK. The post Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stockEquity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the first half of 2024 NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV)Phase 1 trial to commence in the first half of 2024Nature Partner Journals (NPJ) Vaccines published peer-reviewed preclinical data that provides a preclinical proof of concept for the trial as the tested, representative vaccine design was safe, immunogenic, and efficacious NEW YORK and VIENNA, Austria, Nov. 2

Financial Performance and Business Highlights for the Third Quarter

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials

HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here's what investors need to ...

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were high quality, durable and suggest an association with clinical benefit based on disease control Totality of data reinforce the value proposition of HOOKIPA’s arenaviral platform in driving T cell responses necessary for tumor control NEW YORK and VIENNA, Austria, Nov. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIP

Gainers American Well (NYSE:AMWL) stock moved upwards by 22.9% to $1.16 during Thursday's after-market session. American Well's trading ...

Analysts have provided the following ratings for HOOKIPA Pharma (NASDAQ:HOOK) within the last quarter: Bullish Somewhat ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks to sell are a dime a dozen and very risky which is why September is a great time to offload them. The post 7 Biotech Stocks to Sell in September Before They Crash & Burn appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement It doesn’t matter if you have $500 or $5 million. Do this now.

The Dow Jones closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or ...

The Dow Jones closed lower by over 180 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern ...

The Dow Jones closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or ...

The Dow Jones closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around ...

Gainers First Wave BioPharma (NASDAQ:FWBI) stock moved upwards by 79.7% to $2.05 during Tuesday's regular session. The current volume ...

Analysts have provided the following ratings for HOOKIPA Pharma (NASDAQ:HOOK) within the last quarter: Bullish Somewhat ...

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the company’s CFO for the past five years, is stepping down as CFO today and will leave the company June 2.

HOOKIPA Pharma (NASDAQ:HOOK) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:01 AM. Here's what investors need to know ...

HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Thursday, 2023-05-11. Here's what investors need to ...

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 238.9% to $6.88 during Friday's regular session. As of 13:30 EST, Nanobiotix's stock is ...

According to data from Benzinga Pro, during Q4, HOOKIPA Pharma's (NASDAQ:HOOK) reported sales totaled $7.83 million. Despite a 32.65% ...

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share ...

HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Wednesday, 2023-03-15. Here's what investors need to ...

Gainers Molecular Templates (NASDAQ:MTEM) shares rose 31.9% to $0.62 during Friday's pre-market session. The company's market cap ...

Gainers Calyxt (NASDAQ:CLXT) stock increased by 140.3% to $0.45 during Tuesday's pre-market session. The company's market cap stands at ...

Gainers Brainstorm Cell (NASDAQ:BCLI) stock moved upwards by 20.6% to $2.05 during Friday's after-market session. The market value of ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares rose 55.1% to $0.1578 in pre-market trading after dipping around 48% on Tuesday. ...

The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the pace with technology.

On Thursday, shares of HOOKIPA Pharma Inc. (NASDAQ: HOOK) experienced volatile short activity. After the activity, the stock price went ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indonesia Energy (INDO) stock is climbing higher on Thursday after the company announced the discovery of oil in one of its new wells. The post Why Is Indonesia Energy (INDO) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hookipa (HOOK) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (RHHBF). The post Why Is Hookipa (HOOK) Stock Up 26% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.